$CNTA News
Last published 4mo ago
- 4mo agoCNTAAcquisition of Centessa by Lilly Approved by the High Court of Justice of England and WalesGlobeNewswireBOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other
- 5mo agoLLYCNTAEli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areasCNBCEli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable pharmaceutical company in the world.
- 5mo agoATNMCNTAActinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline DevelopmentPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today...
- 7mo agoLLYCNTALilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disordersPR NewswireEli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for...
- 9mo agoCNTACentessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today
- 10mo agoCNTACentessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual MeetingGlobeNewswireBOSTON and LONDON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company focused on developing transformational medicines, today announced the
- 11mo agoCNTACentessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience IndicationsGlobeNewswireBOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company, today announced that its Board of Directors has appointed Mario Alberto Accardi
- 1y agoCNTACentessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary SharesGlobeNewswireBOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company, today announced the pricing of an underwritten public offering of 11,627,907
- 1y agoCNTACentessa Pharmaceuticals Announces Proposed Public Offering of American Depositary SharesGlobeNewswireBOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an underwritten public offering of
- 1y agoCNTACentessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today
- 1y agoCNTACentessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist ProgramGlobeNewswireORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust
- 1y agoCNTACentessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceGlobeNewswireBOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today
- 1y agoCNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025GlobeNewswireAdvancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy
- 1y agoCNTACentessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this YearGlobeNewswireBOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the
- 1y agoCNTACentessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today
- 1y agoCNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025GlobeNewswireAdvancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy
- 1y agoCNTACentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024GlobeNewswireAdvancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type
- 1y agoCNTACentessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual MeetingGlobeNewswireBOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for
- 1y agoCNTACentessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today
- 1y agoCNTACentessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical OfficerGlobeNewswireBOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are
- 1y agoCNTACentessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business UpdateGlobeNewswireAnnounced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in acutely sleep-deprived healthy volunteers that further support best-in-class potential of
- 2y agoCNTACentessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today
- 2y agoCNTACentessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)GlobeNewswireLate-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric
- 2y agoCNTACentessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary SharesGlobeNewswireBOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for
- 2y agoCNTACentessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary SharesGlobeNewswireBOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for
- 2y agoCNTACentessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy VolunteersGlobeNewswire2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT)Favorable safety and tolerability profile with no observations of frequently
- 2y agoCNTACentessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)GlobeNewswireBOSTON and LONDON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced that preclinical data from a non-human primate (NHP) study of ORX142, a highly potent and selective
- 2y agoCNTACentessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewswireBOSTON and LONDON, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today
- 2y agoCNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024GlobeNewswireCompany advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists Initiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and efficacy data in acutely
- 2y agoCNTACentessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business OfficerGlobeNewswireBOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for
- 2y agoCNTACentessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today
- 2y agoCNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024GlobeNewswireHemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024Orexin Agonist Program: Cleared IND and initiated Phase
- 2y agoCNTACentessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary SharesGlobeNewswireBOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for
- 2y agoCNTACentessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary SharesGlobeNewswireBOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for
- 2y agoCNTACentessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024GlobeNewswireBOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for
- 2y agoCNTACentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023GlobeNewswireHemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024Orexin Agonist Program: Clinical
- 2y agoCNTACentessa Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care ConferenceGlobeNewswireBOSTON and LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today
- 2y agoCNTACentessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)GlobeNewswireBOSTON & LONDON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA) announced that data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing
- 2y agoCNTACentessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON and LONDON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today
- 2y agoCNTACentessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBOSTON and LONDON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today
- 2y agoCNTACentessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of HemophiliaGlobeNewswirePart 5 data reinforces favorable safety and tolerability profile and long-term efficacy results for SerpinPC: Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline No thromboembolic events or
- 2y agoANABCNTAAnaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa PharmaceuticalsGlobeNewswireAnaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolioIND filing to support clinical development of ANB101 in autoimmune and inflammatory
- 2y agoCNTACentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023GlobeNewswireSerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentation at American Society of Hematology (ASH) Annual
- 3y agoCNTACentessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual MeetingGlobeNewswireBOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA) today announced that new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the
- 3y agoCNTACentessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with InhibitorsGlobeNewswireBOSTON and LONDON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for
- 3y agoCNTACentessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON and LONDON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today
- 3y agoCNTACentessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake DisordersGlobeNewswire- Preclinical data demonstrated significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 (NT1) - ORX750 advancing in IND-enabling studies; Clinical proof of concept data
- 3y agoCNTACentessa Pharmaceuticals Announces Additions to Senior Leadership TeamGlobeNewswireBOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for
- 3y agoCNTACentessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewswireBOSTON and LONDON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today
- 3y agoCNTACentessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep CongressGlobeNewswireBOSTON and LONDON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for